| 41.18 0.53 (1.3%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.68 | 1-year : | 60.36 |
| Resists | First : | 44.25 | Second : | 51.68 |
| Pivot price | 40.03  |
|||
| Supports | First : | 39.5 | Second : | 36.58 |
| MAs | MA(5) : | 40.2  |
MA(20) : | 40.56 |
| MA(100) : | 41.02 |
MA(250) : | 31.84 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 51.6 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 47.73 | Low : | 18.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IDYA ] has closed below upper band by 33.4%. Bollinger Bands are 29% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.48 - 42.68 | 42.68 - 42.87 |
| Low: | 39.95 - 40.18 | 40.18 - 40.4 |
| Close: | 40.81 - 41.16 | 41.16 - 41.5 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Wed, 01 May 2024
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event - Yahoo Canada Finance
Fri, 26 Apr 2024
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wed, 24 Apr 2024
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma ... - Morningstar
Mon, 22 Apr 2024
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in ... - PR Newswire
Tue, 12 Mar 2024
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in ... - PR Newswire
Fri, 23 Feb 2024
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 7.378e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 8,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3195e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 68.7 % |
| Return on Equity (ttm) | -16.3 % |
| Qtrly Rev. Growth | 2.339e+007 % |
| Gross Profit (p.s.) | -3.13 |
| Sales Per Share | -29.11 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.42 |
| Price to Cash Flow | 3.44 |
| Dividend | 0 |
| Forward Dividend | 9.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|